Edgewise Therapeutics reports positive updates from HCM drug EDG-7500

CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM

Abbott’s Volt PFA System gets FDA nod

AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life

SRM Global Hospitals performs Tamil Nadu’s first TactiFlex radiofrequency ablation to save 80-yr-old patient

TactiFlex, the world’s first catheter with a flexible tip and contact?force sensing, allows doctors to deliver energy precisely and safely.

Bristol Myers Squibb to provide Eliquis free to Medicaid

The pharma company will donate more than seven tons of its active pharmaceutical ingredient (API) to bolster the American supply chain

Lilly drug cuts risk of disease progression or death by 80% in trial

The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study

Bristol Myers Squibb, Johnson & Johnson halt major heart-drug trial after disappointing results

Winrevair cuts risk of PAH progression by 76% in phase 3 Hyperion trial

Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine

Bristol Myers Squibb to present new cardiovascular data at ESC Congress 2025

FDA approves Bayer’s Finerenone for new indication in patients with HF and LVEF of ?40%

Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,

Merck announces Phase 3 hyperion study of Winrevair met primary endpoint in recently diagnosed adults with PAH

WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy